secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lomond Therapeutics Holdings, Inc. (—)
CIK:        0001900520
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001213900-26-003908
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lomond invests $9M in Idwal Therapeutics for Series A preferred units; option for $2M additional
--------------------------------------------------------------------------------

- Lomond purchased 3.1M Series A Preferred Units of Idwal at $2.90/unit for ~$9.0M; closing occurred Jan 8, 2026.
- Idwal formed with MALT-1 program assets from Tegid Therapeutics; total gross proceeds ~$47M from all investors.
- Lomond has option to invest additional ~$2.0M on same terms.
- Initial managers of Idwal are Lomond's directors: Iain Dukes, Nikolay Savchuk, Carl Gordon, Eddie Wang Rodriguez.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/0001213900-26-003908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1900520/000121390026003908/ea0272638-8k_lomond.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-003908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer